As HHS Secretary, Nominee Burwell Would Preside Over ACA Policy Revisions
Executive Summary
OMB Director Sylvia Burwell is nominated to take the helm at HHS, where she would manage future evolutions in the exchange plans, including possible changes to drug coverage policies that would be effective in 2016.
You may also be interested in...
Track-And-Trace: With Deadline A Year Away, Some Lessons From Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.